Hartmut Goldschmidt

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 95 Citations 42,519 829 World Ranking 6045 National Ranking 318

Overview

What are the main themes of his work throughout his whole career to date

Oncology and Gastroenterology are two areas of study in which Hartmut Goldschmidt engages in interdisciplinary work. He performs multidisciplinary study in the fields of Gastroenterology and Internal medicine via his papers. He regularly links together related areas like Thalidomide in his Internal medicine studies. Hartmut Goldschmidt performs multidisciplinary studies into Thalidomide and Lenalidomide in his work. He combines Lenalidomide and Dexamethasone in his research. His work blends Dexamethasone and Chemotherapy studies together. While working in this field, Hartmut Goldschmidt studies both Chemotherapy and Salvage therapy. His research on Salvage therapy often connects related topics like Surgery. Surgery and Transplantation are commonly linked in his work.

Hartmut Goldschmidt most often published in these fields:

Oncology (100.00%)
Transplantation (100.00%)
Multiple myeloma (100.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

3617 Citations

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)

2991 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1673 Citations

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)

1531 Citations

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel.
The New England Journal of Medicine (2016)

1345 Citations

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)

913 Citations

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy.
Lancet Oncology (2013)

912 Citations

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)

865 Citations

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
Blood (2016)

721 Citations

Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.

Rainer Haas;Robert Möhle;Stefan Frühauf;Hartmut Goldschmidt.
Blood (1994)

699 Citations

If you think any of the details on this page are incorrect, let us know.